Axsome and Teva Reach Settlement Agreement on AUVELITY Licensing
In a significant development for the pharmaceutical industry, Axsome Therapeutics and Teva have reached a historic settlement agreement regarding AUVELITY. This resolution effectively ends all patent litigation over AUVELITY, paving the way for Teva to enter the market with a generic version of the drug under certain conditions.
Key Terms of the Settlement Agreement
The agreement stipulates that Teva will receive a license to sell its generic version of AUVELITY under specific circumstances. If pediatric exclusivity is granted for AUVELITY, Teva may begin marketing its generic starting March 31, 2039. Should no pediatric exclusivity be granted, the start date for Teva’s sales moves to September 30, 2038. These dates are subject to final FDA approval and adherence to the typical conditions and exceptions found in such agreements.
Resolution of Patent Litigation
This settlement agreement marks the end of all ongoing legal battles between Axsome and Teva concerning AUVELITY patents in the U.S. District Court for the District of New Jersey. The resolution signifies a significant milestone in the company’s journey to address patent disputes effectively.
Statement from Axsome Therapeutics
“Axsome is proud of its commitment to innovating treatments aimed at improving the lives of millions of patients struggling with central nervous system disorders,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. “The resolution of this patent litigation underscores the value of our innovation in relation to AUVELITY and reflects the strength of Axsome’s intellectual property portfolio. Moving forward, we look forward to continuing to serve our communities through innovative and differentiated new medicines, building upon our robust neuroscience pipeline that addresses a wide range of serious neurological and psychiatric conditions impacting over 150 million Americans.”
Regulatory Review Process
As mandated by law, Axsome and Teva must submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Ensuring the agreement complies with antitrust laws is a crucial step in finalizing the settlement.
About Axsome Therapeutics
Axsome Therapeutics stands at the forefront of biopharmaceutical innovation, dedicated to improving patients’ lives through advancements in the treatment of central nervous system (CNS) conditions. The company focuses on填补 critical gaps in medical care with differentiated products that offer novel mechanisms of action, leading to significant improvements in patient outcomes. Currently, Axsome’s FDA-approved treatments address major depressive disorder and excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The corporation’s late-stage pipeline encompasses further programs designed to treat a broad spectrum of serious neurological and psychiatric conditions.
To learn more about Axsome Therapeutics and its mission to solve some of the brain’s greatest challenges, visit the company’s official website at www.axsome.com.
Contact Information
Investors
For inquiries from investors, please reach out to:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media
For media inquiries, contact:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
Next Steps
The settlement represents a pivotal point in the lifecycle of AUVELITY, offering hope for patients to access more affordable treatment options. As Axsome and Teva navigate the regulatory review process, the medical community and patients eagerly await the outcomes of their efforts. This agreement not only brings closure to the patent disputes but also strengthens Axsome’s position in the market, showcasing its commitment to innovation and patient care.
Join the Discussion
We invite you to share your thoughts on this groundbreaking settlement. Your insights and questions are valuable to us and contribute to our ongoing conversation about the future of pharmaceutical innovation. Don’t hesitate to leave your comments below! If you enjoyed this article, consider subscribing to our newsletter to stay informed about the latest developments in healthcare and biotech. Don’t forget to like and share this article on your preferred social media channels to spread the word and support our mission of bringing quality news to our community. Let’s continue to drive positive change together!
